Overview

Study of Jitongning Tablet to Treat Spondyloarthritis

Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.
Phase:
Phase 2
Details
Lead Sponsor:
Tasly Pharmaceuticals, Inc.